Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients

URL

https://www.imrpress.com/journal/RCM/22/3/10.31083/j.rcm2203116/htm

Authors

Matthieu Million, Jean-Christophe Lagier, Hervé Tissot Dupont, Isabelle Ravaux, Catherine Dhiver, Christelle Tomei, Nadim Cassir, Léa DeLorme, Sébastien Cortaredona, Sophie Amrane, Camille Aubry, Karim Bendamardji, Cyril Berenger, Barbara Doudier, Sophie Edouard, Marie Hocquart, Morgane Mailhe, Coralie Porcheto, Piseth Seng, Catherine Triquet, Stéphanie Gentile, Elisabeth Jouve, Audrey Giraud-Gatineau, Herve Chaudet, Laurence Camoin-Jau, Philippe Colson, Philippe Gautret, Pierre-Edouard Fournier, Baptiste Maille, Jean-Claude DeHaro, Paul Habert, Jean-Yves Gaubert, Alexis Jacquier, Stéphane Honore, Katell Guillon-Lorvellec, Yolande Obadia, Philippe Parola, Philippe Brouqui, and Didier Raoult

Published Date

September 24, 2021

Publication

Reviews in Cardiovascular Medicine

Organization

Aix Marseille University (France)

Key Excerpts

"We evaluated the age-specific mortality of unselected adult outpatients infected with SARS-CoV-2 treated early in a dedicated COVID-19 day hospital and we assessed whether the use of hydroxychloroquine (HCQ) + azithromycin (AZ) was associated with improved survival in this cohort... The primary endpoint was 6-week mortality, and secondary endpoints were transfer to the intensive care unit and hospitalization rate. Among 10,429 patients... 16 died (0.15%). The infection fatality rate was 0.06% among the 8315 patients treated with HCQ+AZ. No deaths occurred among the 8414 patients younger than 60 years."

This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).

Medium

document

Topics

COVID-19,hydroxychloroquine,infection fatality rate (IFR),medical treatment protocols,medical treatments,pharmaceuticals